Radar · Oncology in California
Best Oncology Companies in California, United States
The 768 best Oncology companies in California, United States in 2026, ranked by funding and momentum. Funding, investors, founders, valuation, tech stack and live signals. Top: GRAIL.
By Riya SenguptaFinancials
768companies tracked
$42.2Bdisclosed funding
4unicorns
513have raised
FLIAR INTELLIGENCE · ONCOLOGY × CALIFORNIA
Our analysis of 50 Oncology companies
$16.3b in tracked funding; 86% of the stack-profiled cohort runs cloud-native; funding activity peaked in 2025.
50companies analysed
86%cloud-native stacks
2025funding peak (by rounds)
2unicorns
2016median founding year
736kcombined LinkedIn audience
61%of audience held by top 3
9companies hiring publicly (12 mo)
Ranked: Best Oncology companies in California
| # | Company | Disclosed funding | Last round | Stage | Employees | Founder | Patents & IP focus | Recent signals |
|---|---|---|---|---|---|---|---|---|
| 1 | GRAIL Developer of a screening platform for circulating tumor DNA to detect cancer 78Patents top 13%Tech top 16%News top 17%Funding top 20% All 12 signals ▾Patentstop 13% Techtop 16% Newstop 17% Fundingtop 20% Innovationtop 25% Growthtop 36% Markettop 37% Moattop 38% Partnerstop 40% Globaltop 49% Fin. healthbottom 49% Talentbottom 49% Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront rank vs industry peers · Fliar Intelligence Index 78/100 | $2.0B | 7 mo ago | Public | 491 491 → 1,111 (+126%) · sector median +20% | Bob Ragusa Chief Executive Officer | 899 patents Liquid biopsy cancer detection via cfDNA methylation and fragment analysis | — |
| 2 | Rakuten Medical Developer of a photoimmunotherapy platform for treating cancer 69Funding top 12%Moat top 24%Patents top 25%Innovation top 34% All 10 signals ▾Fundingtop 12% Moattop 24% Patentstop 25% Innovationtop 34% Growthtop 35% Newstop 39% Markettop 45% Techtop 46% Talentbottom 49% Globalbottom 42% Funding: Raised $874M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 150 patents rank vs industry peers · Fliar Intelligence Index 69/100 | $874M | 11 mo ago | Series F | 110 110 → 129 (+17%) · sector median +20% | Hiroshi Mikitani Chairman & CEO | 150 patents Photodynamic therapy delivery devices and catheter-based drug administration technologies | — |
| 3 | Summit Developer of therapeutics for oncology and rare diseases 22Partners top 31%Funding top 33%Product top 35%News top 37% All 13 signals ▾Partnerstop 31% Fundingtop 33% Producttop 35% Newstop 37% Techtop 45% Growthbottom 43% Moatbottom 43% Marketbottom 42% Talentbottom 41% Globalbottom 37% Patentsbottom 30% Innovationbottom 26% Fin. healthbottom 22% Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 22/100 | $713M | 7 mo ago | Public | 99 | Maky Zanganeh CEO | 13 patents Digital media submission, processing, and distribution platforms for online content management. | — |
| 4 | Eikon 🦄 Protein tracking and measuring tool for drug discovery 60Funding top 14%News top 28%Moat top 28%Market top 38% All 10 signals ▾Fundingtop 14% Newstop 28% Moattop 28% Markettop 38% Growthtop 40% Techtop 43% Talenttop 44% Globalbottom 42% Patentsbottom 38% Innovationbottom 36% Funding: Raised $668M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) News: 8 BI events in 12 mo (of 23 tracked, 7 types) · +14% YoY rank vs industry peers · Fliar Intelligence Index 60/100 | $668M | 16 mo ago | Public | 331 | Robert Tjian Co-Founder | 9 patents Automated vehicle intrusion barriers for rapid security deployment | — |
| 5 | Guardant Health Developer of digital sequencing technology for cancer detection 90Patents top 14%Funding top 15%Innovation top 17%Moat top 19% All 13 signals ▾Patentstop 14% Fundingtop 15% Innovationtop 17% Moattop 19% Markettop 23% Techtop 23% Newstop 29% Growthtop 30% Producttop 35% Fin. healthtop 36% Partnerstop 41% Globaltop 45% Talenttop 46% Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 90/100 | $557M | 7 mo ago | Public | 1,351 | Amirali Talasaz Co-founder and Co-Chief Executive Officer | 996 patents Liquid biopsy cfDNA sequencing and analysis for cancer detection and monitoring | 1 launch · 1 partnership |
| 6 | Lyell Immunopharma Developer of CAR- T therapy for cancer treatment 45Patents top 14%Innovation top 21%Funding top 24%Talent top 28% All 11 signals ▾Patentstop 14% Innovationtop 21% Fundingtop 24% Talenttop 28% Techtop 30% Moatbottom 46% Globalbottom 42% Marketbottom 32% Growthbottom 32% Newsbottom 23% Fin. healthbottom 18% Patents: 163 patents matched (strict assignee match) · 154 filings since 2022 vs 9 in 2017-21 Innovation: 163 patents (top 13% of patent-holders) · 154 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $493M | 10 mo ago | Public | 224 224 → 233 (+4%) · sector median +20% | Stan Riddell Co-Founder | 163 patents Patents concentrated in chemistry & materials | — |
| 7 | Inhibrx Antibody-based immunotherapeutics for cancer and infectious diseases 45Funding top 25%Patents top 29%Product top 32%Innovation top 33% All 11 signals ▾Fundingtop 25% Patentstop 29% Producttop 32% Innovationtop 33% Techtop 42% Moatbottom 49% Growthbottom 43% Marketbottom 41% Globalbottom 40% Newsbottom 32% Fin. healthbottom 31% Funding: Raised $469M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) Patents: 499 patents matched (strict assignee match) · 161 filings since 2022 vs 269 in 2017-21 rank vs industry peers · Fliar Intelligence Index 45/100 | $469M | 15 mo ago | Acquired | 112 112 → 111 (-1%) · sector median +20% | — | 499 patents Engineering multispecific therapeutic proteins (antibodies, DR5, serpin fusions) for immune modulation | 1 launch |
| 8 | TORL BioTherapeutics Developer of antibody-based therapeutics for the treatment of cancer 37Funding top 16%Moat top 31%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 16% Moattop 31% Talentbottom 49% Marketbottom 40% Globalbottom 29% Funding: Raised $350M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 37/100 | $350M | 8 mo ago | Series C | — | Mark Attanasio Co-Founder | — | — |
| 9 | Orca Bio 🦄 Developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders 74Funding top 18%Growth top 26%Moat top 26%Talent top 38% All 8 signals ▾Fundingtop 18% Growthtop 26% Moattop 26% Talenttop 38% Techtop 40% Markettop 42% Globalbottom 37% Newsbottom 18% Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 74/100 | $300M | 5 mo ago | Series F | 66 | Jeroen Bekaert Co-Founder & COO | — | 1 expansion |
| 10 | Sorrento Therapeutics Developer of immuno therapeutics for cancer, inflammation, and autoimmune diseases 67Funding top 20%Patents top 20%Market top 26%Moat top 30% All 12 signals ▾Fundingtop 20% Patentstop 20% Markettop 26% Moattop 30% Innovationtop 32% Growthtop 45% Fin. healthtop 45% Partnerstop 45% Talentbottom 49% Globalbottom 44% Techbottom 31% Newsbottom 27% Funding: Raised $282M across 17 rounds · 17 rounds over 17 yrs (1.0/yr) Patents: 1,073 patents matched (strict assignee match) · 312 filings since 2022 vs 587 in 2017-21 rank vs industry peers · Fliar Intelligence Index 67/100 | $282M | 14 mo ago | Public | 949 | Henry Ji Co-Founder & CEO | 1,073 patents Patents concentrated in health & consumer products | — |
| 11 | BlossomHill Therapeutics Provider of the drug for the treatment of oncology and autoimmune disorders 55Funding top 20%Patents top 21%Innovation top 23%Moat top 26% All 7 signals ▾Fundingtop 20% Patentstop 21% Innovationtop 23% Moattop 26% Newsbottom 42% Globalbottom 42% Marketbottom 34% Funding: Raised $260M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) Patents: 133 patents matched (strict assignee match) · 133 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 55/100 | $260M | 6 mo ago | Series B | 14 | — | 133 patents Patents concentrated in chemistry & materials | 3 job openings |
| 12 | Terremoto Developer of small-molecule therapeutics for cancer treatment 60Funding top 15%Talent top 28%Moat top 31%Growth top 35% All 7 signals ▾Fundingtop 15% Talenttop 28% Moattop 31% Growthtop 35% Techtop 49% Marketbottom 41% Globalbottom 36% Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 60/100 | $250M | 2 mo ago | Series C | 35 | Matt Jacobson Co-Founder | — | — |
| 13 | Avenzo Therapeutics Developer of therapeutics for cancer treatment | $223M | 9 mo ago | Series B | 8 | Mohammad Hirmand Co-Founder & Chief Medical Officer | — | 1 job opening |
| 14 | A2 Biotherapeutics Developer of antigen-specific therapy for cancer treatment | $208M | 17 mo ago | Series C | 137 | Jim Robinson Chief Executive Officer | 74 patents Engineered immune cell receptors and chimeric CARs for targeted cancer immunotherapy | 1 job opening |
| 15 | Iambic Therapeutics Provider of AI-driven drug discovery platform for the treatment of cancer 60Funding top 15%AI top 26%Moat top 31%Talent top 38% All 9 signals ▾Fundingtop 15% AItop 26% Moattop 31% Talenttop 38% Growthtop 45% Marketbottom 43% Newsbottom 43% Techbottom 40% Globalbottom 39% Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) AI: Classified as an AI company · Product described with: ai driven, ai-driven rank vs industry peers · Fliar Intelligence Index 60/100 | $206M | 2 mo ago | Series C | 50 | Fred Manby Co-Founder & CTO | — | — |
| 16 | MEI Pharma Developer of targeted therapies for the treatment of cancer | $204M | 11 mo ago | Public | 46 46 → 110 (+139%) · sector median +20% | — | 329 patents Novel CDK9 inhibitor polymorphs and oncology combination therapies (PI3K/PD‑1). | — |
| 17 | Solve Therapeutics Developer of antibody-based therapies targeting tumor-specific antigens for cancer treatment 55Funding top 16%Moat top 40%Global top 45%Market bottom 49% All 5 signals ▾Fundingtop 16% Moattop 40% Globaltop 45% Marketbottom 49% Talentbottom 49% Funding: Raised $195M across 2 rounds · 2 rounds over 2 yrs (1.0/yr) Moat: Soonicorn · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 55/100 | $195M | 7 mo ago | Series D | — | Dave Johnson Founder & CEO | — | — |
| 18 | ORIC Pharmaceuticals Developer of small-molecule drugs for the treatment of cancers | $173M | 12 mo ago | Public | 86 86 → 135 (+57%) · sector median +20% | — | 229 patents Small-molecule oncology drugs targeting epigenetic regulators, EGFR mutants, CD73, and AKT pathways. | — |
| 19 | Plexium Precision medicine company pioneering targeted protein degradation therapeutics | $165M | 11 mo ago | Series B | 81 | Andrew MacConnell Co-Founder | 121 patents Epigenetic protein degraders and oligonucleotide‑encoded small‑molecule discovery platforms | — |
| 20 | Attovia Developer of antibody-based therapeutics for immune-mediated diseases and oncology 48Funding top 19%Talent top 28%Moat top 38%Global bottom 38% All 5 signals ▾Fundingtop 19% Talenttop 28% Moattop 38% Globalbottom 38% Marketbottom 37% Funding: Raised $165M across 3 rounds · 3 rounds over 2 yrs (1.5/yr) Talent: 3 named leaders on record · 3 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 48/100 | $165M | 14 mo ago | Series C | — | Zaneta Odrowaz Co-Founder | — | — |
| 21 | Enlaza Developer of protein therapeutics for the treatment of cancer and other serious diseases | $161M | 9 mo ago | Series A | 39 | Sanford Madigan Co-Founder | — | — |
| 22 | Senti Bio Developer of cell and gene therapies for patients living with incurable diseases 45Product top 14%Funding top 21%Talent top 22%Tech top 32% All 11 signals ▾Producttop 14% Fundingtop 21% Talenttop 22% Techtop 32% Innovationtop 34% Newsbottom 43% Moatbottom 43% Growthbottom 39% Globalbottom 39% Marketbottom 32% Fin. healthbottom 20% Product: 4 distinct product lines · Company stage: Public Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) rank vs industry peers · Fliar Intelligence Index 45/100 | $158M | 1 mo ago | Public | 122 | Jim Collins Co-Founder | — | — |
| 23 | Arthrosi Therapeutics Developer of therapeutics for gout, chronic kidney diseases, and oncology 22Funding top 26%News top 46%Moat top 48%Talent bottom 49% All 7 signals ▾Fundingtop 26% Newstop 46% Moattop 48% Talentbottom 49% Techbottom 43% Globalbottom 37% Marketbottom 24% Funding: Raised $140M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) News: 2 BI events in 12 mo (of 6 tracked, 3 types) · +100% YoY rank vs industry peers · Fliar Intelligence Index 22/100 | $140M | 12 mo ago | Acquired | 11 | Litain Yeh Co-Founder & CEO | — | — |
| 24 | ARTBIO Develoer of alpha radioligand therapies for cancer treatment | $113M | 10 mo ago | Series B | — | Roy Larsen Co-Founder | 11 patents Radiopharmaceutical production, handling, and delivery systems for medical imaging and therapy | — |
| 25 | Galvanize Developer of pulsed electric field systems for various medical indications | $110M | 11 mo ago | Series C | 114 | Jonathan Waldstreicher Founder & CEO | — | — |
| 26 | Adela Developer of a platform for detection of cancer 57Funding top 22%Moat top 31%Patents top 38%Talent top 38% All 8 signals ▾Fundingtop 22% Moattop 31% Patentstop 38% Talenttop 38% Markettop 46% Innovationtop 49% Globalbottom 40% Newsbottom 22% Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents rank vs industry peers · Fliar Intelligence Index 57/100 | $109M | 2 mo ago | Series A | 62 | Manish Agarwal Co-Founder | 15 patents Liquid biopsy nucleic acid extraction and sequencing library preparation technologies | 1 job opening · 1 partnership |
| 27 | TEMPEST THERAPEUTICS Developing targeted, immune-mediated oral cancer therapies for broad patient benefit 21Funding top 28%News top 36%Growth top 42%Tech top 49% All 9 signals ▾Fundingtop 28% Newstop 36% Growthtop 42% Techtop 49% Moatbottom 43% Talentbottom 41% Globalbottom 39% Marketbottom 23% Fin. healthbottom 13% Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY rank vs industry peers · Fliar Intelligence Index 21/100 | $88M | 2 mo ago | Public | 19 | Stephen B Chief Executive Officer | — | — |
| 28 | TRexBio Developer of therapeutics for immunology and cancer 45Funding top 20%Moat top 31%News top 46%Talent bottom 49% All 6 signals ▾Fundingtop 20% Moattop 31% Newstop 46% Talentbottom 49% Marketbottom 47% Globalbottom 36% Funding: Raised $85.0M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 45/100 | $85M | 4 mo ago | Series B | 65 | Johnston Erwin CEO | — | — |
| 29 | Electra Therapeutics Developer of therapies for immunological diseases and cancer | $84M | 8 mo ago | Series C | 4 | Adam Rosenthal Co-Founder & CEO | — | 1 launch |
| 30 | Azalea Therapeutics Developer of precision genome engineering technologies for in vivo cell therapies 62Talent top 23%Funding top 26%Global bottom 33% All 3 signals ▾Talenttop 23% Fundingtop 26% Globalbottom 33% Talent: 6 named leaders on record · 6 C-suite/founder profiles curated Funding: Raised $82.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 62/100 | $82M | 7 mo ago | Series A | — | Jenny H Co-Founder | — | 1 expansion |
| 31 | EpiBiologics Developer of antibody-based targeted therapies to treat multiple diseases 45Funding top 21%Talent top 38%Moat top 39%Innovation top 42% All 7 signals ▾Fundingtop 21% Talenttop 38% Moattop 39% Innovationtop 42% Patentstop 42% Globalbottom 37% Marketbottom 34% Funding: Raised $73.0M across 3 rounds · 3 rounds over 3 yrs (1.0/yr) Talent: 2 named leaders on record · 2 C-suite/founder profiles curated rank vs industry peers · Fliar Intelligence Index 45/100 | $73M | 5 mo ago | Series B | 22 | Josef Gramespacher Co-Founder | 13 patents Bispecific antibody therapeutics for targeted degradation of EGFR and cMET receptors | 1 job opening |
| 32 | ClearNote Health Developer of non-invasive cancer detection methods 40Moat top 22%Funding top 36%Market top 50%Talent bottom 49% All 5 signals ▾Moattop 22% Fundingtop 36% Markettop 50% Talentbottom 49% Globalbottom 36% Moat: Editorial + unicorn rating 8/10 · Soonicorn Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) rank vs industry peers · Fliar Intelligence Index 40/100 | $70M | 0 mo ago | Series D | 45 | Dave Mullarkey Chief Executive Officer | — | — |
| 33 | Faeth Therapeutics Provider of personalized nutritional programs against cancer | $67M | 10 mo ago | Acquired | 9 | Anand Parikh Founder & CEO | — | — |
| 34 | Link Cell Therapies Developer of CAR-T cell therapies for the treatment of cancer 11Funding top 29%Tech bottom 41%Global bottom 29%Market bottom 19% All 4 signals ▾Fundingtop 29% Techbottom 41% Globalbottom 29% Marketbottom 19% Funding: Raised $60.0M across 1 rounds · 1 rounds over 4 yrs (0.2/yr) Tech: 19 technologies across 3/8 capability areas · Cloud: Cloudflare rank vs industry peers · Fliar Intelligence Index 11/100 | $60M | 6 mo ago | Series A | 8 | — | — | — |
| 35 | Qualigen Developer of therapeutics for the treatments of adult and pediatric cancer | $51M | 8 mo ago | Public | — | Michael Poirier Founder & CEO | 43 patents Extracorporeal whole blood filtration cartridges for pathogen removal and point-of-care diagnostics | — |
| 36 | BridGene Biosciences Developer of small-molecule drugs for the treatment of cancer 69Growth top 20%Patents top 23%Funding top 24%Innovation top 26% All 8 signals ▾Growthtop 20% Patentstop 23% Fundingtop 24% Innovationtop 26% Moattop 28% Talenttop 38% Globalbottom 40% Marketbottom 36% Growth: Headcount 15 → 25 (+67%) across vintages · Fresh capital in last 24 mo Patents: 44 patents matched (strict assignee match) · 35 filings since 2022 vs 9 in 2017-21 rank vs industry peers · Fliar Intelligence Index 69/100 | $50M | 8 mo ago | Series B | 25 25 → 31 (+24%) · sector median +20% | Irene Yuan Co-Founder & Executive Vice President | 44 patents Small-molecule kinase and YAP/TAZ-TEAD inhibitors for targeted cancer therapy | — |
| 37 | LTZ Therapeutics Developer of immunotherapies to treat cancer and other diseases 35Funding top 26%Moat top 39%Talent bottom 49%Market bottom 40% All 5 signals ▾Fundingtop 26% Moattop 39% Talentbottom 49% Marketbottom 40% Globalbottom 36% Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked rank vs industry peers · Fliar Intelligence Index 35/100 | $47M | 1 mo ago | Series B | 23 | Martin Treder Co-Founder | — | 2 job openings |
| 38 | Primmune Therapeutics Developer of immunotherapies for treating cancer 42Funding top 21%Talent top 28%Product top 35%Innovation top 38% All 8 signals ▾Fundingtop 21% Talenttop 28% Producttop 35% Innovationtop 38% Moattop 39% Techbottom 40% Globalbottom 36% Marketbottom 26% Funding: Raised $46.8M across 8 rounds · 8 rounds over 6 yrs (1.3/yr) Talent: Analyst team rating 4/5 · 4 named leaders on record rank vs industry peers · Fliar Intelligence Index 42/100 | $47M | 4 mo ago | Series B | 9 | Stephen Webber Co-Founder | — | — |
| 39 | PreludeDx Provider of risk assessment test for early stage breast cancer 50Funding top 27%Moat top 31%Growth top 32%Product top 46% All 10 signals ▾Fundingtop 27% Moattop 31% Growthtop 32% Producttop 46% Innovationtop 47% Techtop 47% Talentbottom 49% Marketbottom 37% Globalbottom 37% Newsbottom 22% Funding: Raised $46.7M across 6 rounds · 6 rounds over 10 yrs (0.6/yr) Moat: Editorial + unicorn rating 8/10 · Soonicorn rank vs industry peers · Fliar Intelligence Index 50/100 | $47M | 7 mo ago | Series B | 33 | Dan Forche President and CEO | — | — |
| 40 | Artelo Biosciences Modifying lipid-signaling pathways to improve cancer treatments 53Funding top 17%Growth top 20%News top 23%Product top 24% All 9 signals ▾Fundingtop 17% Growthtop 20% Newstop 23% Producttop 24% Innovationtop 43% Talenttop 46% Techbottom 46% Globalbottom 38% Marketbottom 24% Funding: Raised $39.9M across 13 rounds · 13 rounds over 8 yrs (1.6/yr) Growth: Web rank 50,000,000 → 10,000,000 YoY · Fresh capital in last 24 mo rank vs industry peers · Fliar Intelligence Index 53/100 | $40M | 2 mo ago | Public | 7 | Greg Gorgas CEO & President | — | 1 partnership |
| 41 | Daré Bioscience Developer of non-hormonal pharmaceutical products for female contraceptives 50Funding top 27%Product top 28%Growth top 37%Innovation top 38% All 11 signals ▾Fundingtop 27% Producttop 28% Growthtop 37% Innovationtop 38% Techtop 40% Moattop 48% Talentbottom 49% Newsbottom 45% Fin. healthbottom 43% Marketbottom 33% Globalbottom 32% Funding: Raised $39.7M across 17 rounds · 17 rounds over 9 yrs (1.9/yr) Product: 3 distinct product lines · 1 published app (300 installs) rank vs industry peers · Fliar Intelligence Index 50/100 | $40M | 6 mo ago | Public | 30 30 → 27 (-10%) · sector median +20% | Sabrina Johnson President and CEO | — | 4 launchs |
| 42 | Trethera Developer of small molecule cancer therapeutics that target DNA replication and integrity 29Funding top 30%Patents top 37%Moat top 37%Product top 41% All 9 signals ▾Fundingtop 30% Patentstop 37% Moattop 37% Producttop 41% Innovationtop 42% Techtop 47% Talentbottom 49% Globalbottom 33% Marketbottom 18% Funding: Raised $31.0M across 20 rounds · 20 rounds over 11 yrs (1.8/yr) Patents: 15 patents matched (strict assignee match) · 15 filings since 2022 vs 0 in 2017-21 rank vs industry peers · Fliar Intelligence Index 29/100 | $31M | 8 mo ago | Series C | 3 | Ken Schultz Chairman & CEO | 15 patents Patents concentrated in health & consumer products | — |
| 43 | QT Imaging Developer of a non-invasive ultrasound imaging device for detecting breast cancer | $29M | 8 mo ago | Public | 19 | John Klock Chief Executive Officer and Chief Medical Officer | — | — |
| 44 | Athos Therapeutics Developer of AI-based therapeutics for treating autoimmune diseases 35AI top 35%Funding top 36%Talent bottom 49%Moat bottom 45% All 6 signals ▾AItop 35% Fundingtop 36% Talentbottom 49% Moatbottom 45% Marketbottom 32% Globalbottom 25% AI: Product described with: ai-based, machine learning Funding: Raised $28.0M across 3 rounds · 3 rounds over 5 yrs (0.6/yr) rank vs industry peers · Fliar Intelligence Index 35/100 | $28M | 2 mo ago | Series A | 18 | Dimitrios Iliopoulos Co-founder | — | — |
| 45 | OncoSynergy Developer of resistance mechanism inhibitors to treat cancer 11Funding top 28%Moat top 32%Patents bottom 48%Global bottom 42% All 6 signals ▾Fundingtop 28% Moattop 32% Patentsbottom 48% Globalbottom 42% Innovationbottom 33% Marketbottom 18% Funding: Raised $26.7M across 7 rounds · 7 rounds over 8 yrs (0.9/yr) Moat: Editorial + unicorn rating 5/10 · IP moat: 26 patents rank vs industry peers · Fliar Intelligence Index 11/100 | $27M | 1 mo ago | Acquired | 3 | — | 26 patents Patents concentrated in chemistry & materials | — |
| 46 | TwoStep Therapeutics Developer of targeted cancer therapies focusing on solid tumors | $21M | 5 mo ago | Series A | — | Jennifer Cochran Co-Founder | — | — |
| 47 | RyboDyn Developer of immunotherapies for the treatment of cancer 21Talent top 28%Funding top 37%Global bottom 48%Market bottom 15% All 4 signals ▾Talenttop 28% Fundingtop 37% Globalbottom 48% Marketbottom 15% Talent: 3 named leaders on record · 3 C-suite/founder profiles curated Funding: Raised $14.0M across 2 rounds · 2 rounds over 3 yrs (0.7/yr) rank vs industry peers · Fliar Intelligence Index 21/100 | $14M | 2 mo ago | Seed | 3 | Kerry Wilson Co-Founder | — | — |
| 48 | RenovoRx Developer of endovascular catheters for targeted delivery of IV fluids to peripheral organs | $11M | 2 mo ago | Public | 6 | — | 18 patents Targeted intravascular drug delivery via vasa vasorum for cancer and pancreatic therapies | — |
| 49 | Valius Provider of molecular diagnostic testing services for identifying cancer vulnerabilities | $10M | 2 mo ago | Series A | — | Sarah Hesse Co-Founder & Head of Translational Science | — | — |
| 50 | TippingPoint Biosciences Developer of therapeutics for treating diseases caused by dysfunctional genome chromatin packaging | $7M | 2 mo ago | Seed | — | Geeta Narlikar Co-Founder | — | 1 partnership |
Top 12 Oncology companies in California
#1
Public · Menlo Park, California · founded 2016 · 491 employees$2Braised▾
Public · Menlo Park, California · founded 2016 · 491 employees
Developer of a screening platform for circulating tumor DNA to detect cancer. The company is developing a test called "Galleri" a pan-cancer screening test by measuring circulating nucleic acids in the blood. Its proprietary platform uses the ultra-deep sequencing technique to measure levels of circulating tumor DNA in the patient's blood.
Fliar Intelligence Index™ 78how this company ranks against its industry peers
Patents
top 13%Tech
top 16%News
top 17%Funding
top 20%Innovation
top 25%Growth
top 36%Patents: 899 patents matched (strict assignee match) · 523 filings since 2022 vs 371 in 2017-21 · Latest publication 2026
Tech: 51 technologies across 6/8 capability areas · Cloud: Amazon Alb, Amazon Cloudfront · Devops: Nginx
News: 11 BI events in 12 mo (of 75 tracked, 14 types) · +83% YoY · 5 high-value events (IPO/M&A/funding/contracts) in 12 mo
Audience (LinkedIn): 113k LinkedIn followers — 15.3% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$325M
- Nov 2019Series D$390M
- May 2018Series C$300M
- Jun 2017Series B—
Founders & team
Investors
PSP Investments, CPP Investments, Illumina, Arch Venture Partners, Johnson & Johnson Innovation, McKesson Ventures
Tech stack
Amazon CloudfrontAmazon S3Amazon SesAmazon Web ServicesApolloApple Icloud Mail
#2
Public · San Francisco, California · founded 2016 · 122 employees$158Mraised▾
Public · San Francisco, California · founded 2016 · 122 employees
Developer of cell and gene therapies for patients living with incurable diseases. The company has developed its proprietary synthetic biology platform to produce cell and gene therapies for cancer treatment. The company's pipeline is comprised of cell therapies engineered with Gene Circuits to target difficult to treat liquid and solid tumors. It offers CAR-NK-based therapies for multiple cancer and tumors.
Fliar Intelligence Index™ 45how this company ranks against its industry peers
Product
top 14%Funding
top 21%Talent
top 22%Tech
top 32%Innovation
top 34%News
bottom 43%Product: 4 distinct product lines · Company stage: Public
Funding: Raised $158M across 8 rounds · 8 rounds over 8 yrs (1.0/yr) · Last round Post IPO (May 2026)
Talent: Analyst team rating 5/5 · 3 named leaders on record · 3 C-suite/founder profiles curated
Audience (LinkedIn): 12k LinkedIn followers
Funding rounds
- May 2026Post IPO$40M
- Dec 2024Post IPO$37.6M
- Dec 2024Post IPO$10M
- Jun 2024Grant (prize money)$8M
Founders & team
Investors
Matrix Partners China, Mirae Asset, Ridgeback Capital Management, Lux Capital, Gaingels, KB Investment
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAddthisAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform Launch
#3
Series C · San Francisco, California · founded 2021 · 35 employees$250Mraised▾
Series C · San Francisco, California · founded 2021 · 35 employees
Developer of small-molecule therapeutics for cancer treatment. It provides a lysine-targeted covalency platform to develop therapies against known drug targets for oncology.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%Talent
top 28%Moat
top 31%Growth
top 35%Tech
top 49%Market
bottom 41%Funding: Raised $250M across 3 rounds · 3 rounds over 4 yrs (0.8/yr) · Last round Series C (Apr 2026)
Talent: 3 named leaders on record · 3 C-suite/founder profiles curated
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 7k LinkedIn followers
Funding rounds
- Apr 2026Series C$108M
- Nov 2023Series B$175M
- May 2022Series A$75M
Founders & team
Investors
Orbimed, Third Rock Ventures, EcoR1, Novo Holdings, Cormorant Capital, RA Capital Management
Tech stack
All In One SeoAmazon Web ServicesApple Icloud MailBugherdCdnjsCloudflare
#4
Series C · San Diego, California · founded 2019 · 50 employees$206.2Mraised▾
Series C · San Diego, California · founded 2019 · 50 employees
Provider of AI-driven drug discovery platform for the treatment of cancer. It offers an AI driven discovery platform and has discovered two candidates known as IAM-H1, a highly selective and brain penetrant inhibitor of HER2 and its oncogenic mutants, and IAM-C1 a potential first-in-class selective dual CDK2/4 inhibitor to address unmet needs in terms of therapeutic window and treatment resistance in cell cycle driven cancers.
Fliar Intelligence Index™ 60how this company ranks against its industry peers
Funding
top 15%AI
top 26%Moat
top 31%Talent
top 38%Growth
top 45%Market
bottom 43%Funding: Raised $206M across 5 rounds · 5 rounds over 5 yrs (1.0/yr) · Last round Series C (Apr 2026)
AI: Classified as an AI company · Product described with: ai driven, ai-driven
Moat: Editorial + unicorn rating 8/10 · Soonicorn · 10 curated direct competitors tracked
Funding rounds
- Apr 2026Series C$27.8M
- Nov 2025Series C$100M
- Apr 2024Series B$50M
- Oct 2023Series B$103.2M
Founders & team
Investors
Ascenta Capital, Abingworth, Nvidia, Illumina Ventures, Shanda, Catalio Capital Management
Tech stack
Apple Icloud MailCloudflareDocusignGoogle Font ApiGoogle Hosted LibrariesHsts
#5
Public · Redwood City, California · founded 2012 · 1351 employees$557.5Mraised▾
Public · Redwood City, California · founded 2012 · 1351 employees
Developer of digital sequencing technology for cancer detection. The product Guardant360 offers real-time, biopsy-free tumor sequencing for the analysis and identification of tumor-associated treatment options. Also, it has developed analytical tools, including a tumor response map and a mobile-enabled physician portal.
Fliar Intelligence Index™ 90how this company ranks against its industry peers
Patents
top 14%Funding
top 15%Innovation
top 17%Moat
top 19%Market
top 23%Tech
top 23%Patents: 996 patents matched (strict assignee match) · 615 filings since 2022 vs 346 in 2017-21 · Latest publication 2026
Funding: Raised $557M across 7 rounds · 7 rounds over 12 yrs (0.6/yr) · Last round Post IPO (Nov 2025)
Innovation: 996 patents (top 3% of patent-holders) · 615 filings since 2022 vs 346 in 2017-21 · Deep-tech classification: Tech Hardware
Audience (LinkedIn): 275k LinkedIn followers — 37.4% of this cohort's audience
Activity (LinkedIn): 1 product launches · 1 partnerships (incl. Cancer Research UK Science and Innovation and The Royal Marsden NHS Foundation Trust) announced in 12 mo
Funding rounds
- Nov 2025Post IPO$350M
- Nov 2020Post IPO$1B
- Aug 2017Series E$360M
- Jan 2016Series D$100M
Founders & team
Investors
Orbimed, Khosla Ventures, Sequoia Capital, Lightspeed Venture Partners, Formation 8, Heritage Group
Tech stack
Amazon Web ServicesAosApache Http ServerApple Icloud MailBootstrapBugherd
#6
Public · Menlo Park, California · founded 2003 · 99 employees$713Mraised▾
Public · Menlo Park, California · founded 2003 · 99 employees
Developer of therapeutics for oncology and rare diseases. It offers Ivonescimab which combines the effects of immunotherapy via a blockade of PD-1 with the anti-VEGF effect for the treatment of non-small cell lung cancer.
Fliar Intelligence Index™ 22how this company ranks against its industry peers
Partners
top 31%Funding
top 33%Product
top 35%News
top 37%Tech
top 45%Growth
bottom 43%Partners: 3 contract events in 12 mo · Named contractor/client in 3 deals
Funding: Raised $713M across 4 rounds · 4 rounds over 6 yrs (0.7/yr) · Last round Post IPO (Oct 2025)
Product: 0 product launch events in 12 mo, 1 the year before · Company stage: Public
Audience (LinkedIn): 58k LinkedIn followers — 7.9% of this cohort's audience
Funding rounds
- Oct 2025Post IPO$228M
- Sep 2024Post IPO$235M
- Jun 2024Post IPO$200M
- Nov 2020Post IPO$50M
Founders & team
Investors
Akeso
Tech stack
CloudflareFancyboxGodaddyGoogle Font ApiHstsJquery
#7
Series A · San Francisco, California · founded 2021 · 62 employees$108.5Mraised▾
Series A · San Francisco, California · founded 2021 · 62 employees
Developer of a platform for detection of cancer. The company has developed a blood test for genome-wide methylation analysis technology to detect kidney cancer and intracranial brain tumors. It allows distinguishing the informative methylated regions of the genome from non-informative regions and targets for sequencing.
Fliar Intelligence Index™ 57how this company ranks against its industry peers
Funding
top 22%Moat
top 31%Patents
top 38%Talent
top 38%Market
top 46%Innovation
top 49%Funding: Raised $109M across 4 rounds · 4 rounds over 5 yrs (0.8/yr) · Last round Series A (Apr 2026)
Moat: Editorial + unicorn rating 8/10 · IP moat: 15 patents · Soonicorn
Patents: 15 patents matched (strict assignee match) · 13 filings since 2022 vs 0 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 6k LinkedIn followers
Hiring (LinkedIn): 1 hiring post in 12 mo (public) · hiring: Accounts Payable Clerk
Activity (LinkedIn): 1 partnerships announced in 12 mo
Funding rounds
- Apr 2026Series A$5M
- Jun 2025Series A$25.4M
- Jul 2023Series A$48.5M
- Jun 2021Series A$60M
Founders & team
Investors
F-Prime Capital, Orbimed, Deerfield, Decheng Capital, RA Capital Management, LabCorp
#8
Series D · San Diego, California · founded 2016 · 45 employees$70Mraised▾
Series D · San Diego, California · founded 2016 · 45 employees
Developer of non-invasive cancer detection methods. It offers a 5-hydroxymethylcytosine-based epigenomic platform and cell-free DNA-based assays to measure biological changes in cells and detect cancers with high mortality rates when they respond best to treatment.
Fliar Intelligence Index™ 40how this company ranks against its industry peers
Moat
top 22%Funding
top 36%Market
top 50%Talent
bottom 49%Global
bottom 36%Moat: Editorial + unicorn rating 8/10 · Soonicorn
Funding: Raised $70.0M across 2 rounds · 2 rounds over 5 yrs (0.4/yr) · Last round Series D (May 2026)
Market: 45 employees (top 39% of Life Sciences)
Audience (LinkedIn): 6k LinkedIn followers
Funding rounds
- May 2025Series C$21.8M
- May 2021Series C$70M
Founders & team
Investors
Pathology Asia Holdings
#9
Orca Bio 🦄Series F · Menlo Park, California · founded 2016 · 66 employees$300Mraised▾
Orca Bio 🦄
Series F · Menlo Park, California · founded 2016 · 66 employees
Orca Bio is a developer of Allogeneic cell therapy for cancer, autoimmune diseases and genetic blood disorders. It uses OrcaSort technology that is an enabling feature for the scalability and high-precision of the manufacturing platform. It also helps in the isolation and purification of stem cells and immune cells used in hematopoietic cell grafts. The components of the technology are optimized for performance and designed to fit seamlessly into the clinical processing of apheresis products. It has developed therapeutic solutions for regulatory T cells that aims to temper the immune reaction. It reduces the fatal complications and provides maximum control of the development of the patient's new immune system.
Fliar Intelligence Index™ 74how this company ranks against its industry peers
Funding
top 18%Growth
top 26%Moat
top 26%Talent
top 38%Tech
top 40%Market
top 42%Funding: Raised $300M across 2 rounds · 2 rounds over 7 yrs (0.3/yr) · Last round Series F (Jan 2026)
Growth: Headcount 39 → 66 (+69%) across vintages · Fresh capital in last 24 mo
Moat: Editorial + unicorn rating 9/10 · Unicorn · 10 curated direct competitors tracked
Audience (LinkedIn): 24k LinkedIn followers — 3.3% of this cohort's audience · 158 engagements/post (3.2× cohort median)
Activity (LinkedIn): 1 expansions announced in 12 mo
Funding rounds
- Jan 2026Series F$250M
- Nov 2019Series D$192M
Founders & team
Investors
Lightspeed Venture Partners, 8VC, DCVC, ND Capital, IMRF, Kaiser Permanente
Tech stack
Amazon Web ServicesApple Icloud MailBackbone.JsBrizy WordpressBunnyBunny Fonts
#10
Public · San Francisco, California · founded 2011 · 19 employees$88.2Mraised▾
Public · San Francisco, California · founded 2011 · 19 employees
Developing targeted, immune-mediated oral cancer therapies for broad patient benefit. This clinical-stage biotechnology company focuses on creating small molecule therapeutics to treat cancer. Their approach involves mechanisms that directly target and kill tumor cells while simultaneously activating the body's own tumor-specific immunity. The company is developing first-in-class oral drug therapeutics with the potential to offer significant advantages to a wide range of cancer patients. They explore both new and validated pathways to discover and develop novel therapeutics. Their pipeline represents innovative approaches to cancer treatment, aiming to improve patient outcomes through targeted and immune-mediated strategies. The company's focus is on oncology drug discovery and development, with the goal of advancing novel therapeutics that will bring meaningful benefit to patients.
Fliar Intelligence Index™ 21how this company ranks against its industry peers
Funding
top 28%News
top 36%Growth
top 42%Tech
top 49%Moat
bottom 43%Talent
bottom 41%Funding: Raised $88.2M across 4 rounds · 4 rounds over 15 yrs (0.3/yr) · Last round Post IPO (Mar 2026)
News: 19 BI events in 12 mo (of 57 tracked, 7 types) · +6% YoY · 6 high-value events (IPO/M&A/funding/contracts) in 12 mo
Growth: Web rank 5,000,000 → 10,000,000 YoY · 2 acquisition/expansion moves in 24 mo · Fresh capital in last 24 mo
Funding rounds
- Mar 2026Post IPO$6M
- Mar 2026Post IPO$2M
- Feb 2020Series B$83.2M
- 2015Series A—
Founders & team
Investors
F-Prime Capital, Lilly Asia Ventures, Foresite Capital, Eight Roads Ventures, Versant Ventures, Quan Capital
Tech stack
Acquia Cloud PlatformAcquia Cloud Site FactoryAdobe AnalyticsAdobe Experience Platform Identity ServiceAdobe Experience Platform LaunchAkamai
#11
Series F · San Mateo, California · founded 2013 · 110 employees$874.3Mraised▾
Series F · San Mateo, California · founded 2013 · 110 employees
Developer of a photoimmunotherapy platform for treating cancer. The company claims that it is developing a technology that combines antibodies with laser-activated precision. The technology induces tumour cell death by inducing an immune response. The company has developed ASP-1929 program for recurrent head and neck squamous cell carcinoma (rHNSCC) and for other cancer types.
Fliar Intelligence Index™ 69how this company ranks against its industry peers
Funding
top 12%Moat
top 24%Patents
top 25%Innovation
top 34%Growth
top 35%News
top 39%Funding: Raised $874M across 12 rounds · 12 rounds over 11 yrs (1.1/yr) · Last round Series F (Jul 2025)
Moat: Editorial + unicorn rating 8/10 · IP moat: 150 patents · Soonicorn
Patents: 150 patents matched (strict assignee match) · 74 filings since 2022 vs 76 in 2017-21 · Latest publication 2026
Audience (LinkedIn): 11k LinkedIn followers · 89 engagements/post (1.8× cohort median)
Funding rounds
- Jul 2025Series F$111.5M
- Mar 2024Series E$119M
- Sep 2023Series D$104.8M
- Dec 2022Series D$70M
Founders & team
Investors
Rakuten, Hikma Pharmaceuticals, Mizuho Bank, Dai-Ichi Life, SBI Group, General Catalyst
Tech stack
Amazon Web ServicesApple Icloud MailCloudflareCloudflare Bot ManagementCookieyesDocusign
#12
Series B · Redwood City, California · founded 2021 · 23 employees$47Mraised▾
Series B · Redwood City, California · founded 2021 · 23 employees
Developer of immunotherapies to treat cancer and other diseases. The company focuses on the development of immunotherapies that are capable of overcoming resistance and boosting anti-tumor immunity based on reverse translational science technology.
Fliar Intelligence Index™ 35how this company ranks against its industry peers
Funding
top 26%Moat
top 39%Talent
bottom 49%Market
bottom 40%Global
bottom 36%Funding: Raised $47.0M across 4 rounds · 4 rounds over 4 yrs (1.0/yr) · Last round Series B (May 2026)
Moat: Editorial + unicorn rating 7/10 · 10 curated direct competitors tracked
Talent: 1 named leader on record · 1 C-suite/founder profile curated
Audience (LinkedIn): 5k LinkedIn followers
Hiring (LinkedIn): 2 hiring posts in 12 mo (public) · momentum +2 · hiring: Finance Coordinator (R&D), Medical/Sr. Med Director (MD) – Early Clinical Development
Activity (LinkedIn): 1 partnerships (incl. GlisoSmithKline (GSK)) announced in 12 mo
Funding rounds
- May 2026Series B$38M
- Jul 2024Series A$20M
- May 2023Seed$10M
- Apr 2022Seed$17M
Founders & team
Investors
Qiming Venture Partners, Shunwei Capital, K2 Venture Capital, Tigermed, Lapam Capital, K2VC
Funding & investor landscape
$42.2Btotal disclosed funding
504companies funded
1,900disclosed rounds
12rounds last 90 days
Most active investors
New Enterprise Associates20 rounds
Notable founders
Bob Ragusa
Chief Executive Officer · GRAIL
Jim Collins
Co-Founder · Senti Bio
Wilson Wong
Co-Founder · Senti Bio
Matt Jacobson
Co-Founder · Terremoto
Jack Taunton
Co-Founder · Terremoto
Fred Manby
Co-Founder & CTO · Iambic Therapeutics
Thomas Miller
Co-Founder & CEO · Iambic Therapeutics
Amirali Talasaz
Co-founder and Co-Chief Executive Officer · Guardant Health
Roberto Mignone
Board of Directors · Guardant Health
Maky Zanganeh
CEO · Summit
Manish Agarwal
Co-Founder · Adela
Scott Bratman
Co-Founder · Adela
Prism market signals · United States · country-scoped Prism corpus, 1,572,524 docs
Market landscape — 10 sub-themes by coverage
Share of Oncology coverage by sub-theme.
Regulatory-risk over time falling
Funding & growth over time
funding rising · growth rising
RESEARCH IN CALIFORNIA · Health & Bio
How research on Oncology in California is moving
A read on the academic research around Oncology in California — which themes are gaining ground, the institutions and researchers driving them, and how the tone is shifting. Based on 888 papers.
UC San Francisco, UCLA, and UC San Diego lead California's optimistic immunotherapy and CAR-T cell cancer research, with breakthroughs dominating and concerns minimal across 888 papers.
888 papers · stance +0.55 · 36% breakthrough · 12% concern
top institutions
- University of California, San Francisco175
- University of California, Los Angeles156
- University of California San Diego138
- University of Southern California92
- University of California, Davis62
leading researchers
Yan-Ruide Li · Wenxue Ma · Takahide Nejo · Yichen Zhu · Akane Yamamichi · Benjamin Bonavida
prism intelligence · tone & topics
97% positive · 1% critical tone
BiotechnologyPharmaceuticalsClinical TrialsMedical ResearchHealthHealthcare
▲
Breakthroughs299 · 34%
▲ 25%→34% share
▲1.4× share momentum1 median citations91% since 2021mostly methods-led
Tumor microenvironment research is surging — breakthrough papers rose from 7 to 121 in California oncology.
rising sub-themes (early→recent)
- Tumor microenvironment7→121
- Immunotherapy5→110
- Immune system2→93
- Cancer research11→78
- Cancer immunotherapy1→62
Newly emergingT cell 0→16 · Reprogramming 0→14 · Glioma 0→14
Landmark Systematic pan-cancer analysis of tumour purity · 1,284 cites
◆
Advancements424 · 48%
▲ 44%→49% share
▲1.1× share momentum1 median citations90% since 2021mostly empirical
Transcriptome analysis newly emerged with 26 advancement papers, signaling rising multi-omic cancer profiling.
rising sub-themes (early→recent)
- Tumor microenvironment9→192
- Immune system6→162
- Immunotherapy10→138
- Cancer research17→138
- Cancer4→79
Newly emergingTranscriptome 0→26 · T cell 0→19 · Colorectal cancer 0→16
Landmark The Senescence-Associated Secretory Phenotype: The Dark Side of Tumor Suppression · 4,937 cites
▼
Concerns97 · 11%
▼ 20%→10% share
▼0.5× share momentum4 median citations82% since 2021mostly reviews
Chimeric antigen receptor research newly flagged — 9 concern papers highlight emerging CAR-T safety scrutiny.
rising sub-themes (early→recent)
- Immunotherapy3→48
- Tumor microenvironment7→45
- Cancer4→33
- Immune system4→30
- Cancer immunotherapy1→20
Newly emergingChimeric antigen receptor 0→9 · Immunology 0→8 · Lung cancer 0→7
Landmark The extracellular matrix: A dynamic niche in cancer progression · 2,974 cites
Common questions
How many Oncology companies are there in California, United States?
Radar tracks 768 indexable Oncology companies headquartered in California, United States that meet our profile-completeness bar.
What is the total funding raised by Oncology companies in California, United States?
The Oncology companies in California, United States on this list have raised a combined $42.2B in disclosed equity funding across 504 funded companies.
Which is the highest-funded Oncology company in California, United States?
GRAIL is the highest-funded Oncology company in California, United States, with $2B in disclosed equity funding.
How many Oncology companies in California, United States are funded?
504 of the 768 Oncology companies in California, United States on this list have disclosed at least one equity funding round.
How many Oncology unicorns are there in California, United States?
4 Oncology companies in California, United States on this list are valued at $1B or more.
Who are the top investors in California, United States Oncology companies?
The most active investors in California, United States Oncology companies on this list include HHS, Orbimed, Foresite Capital, Janus Henderson Investors, RA Capital Management.
Riya SenguptaFinancials
Riya reads income statements for fun. She covers the real money in a sector — revenue, growth, who actually earns — and never met a vague claim she didn't want a number for.